| Project/Area Number |
18390356
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
KONDO Satoshi Hokkaido University, Graduate School of medicine, Professor (30215454)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIANO Satoshi Hokkaido University, Graduate School of medicine, Associate Professor (50322813)
MIYAMOTO Masaki Hokkaido University, Hokkaido University Hospital, Research Associate (40333611)
SHICHINCHE Toshiaki Hokkaido University, Graduate School of medicine, Lecturer (70374353)
HIDA Yasuhiro Hokkaido University, Hokkaido University Hospital, Lecturer (30399919)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥16,670,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2007: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2006: ¥10,300,000 (Direct Cost: ¥10,300,000)
|
|---|
| Keywords | cancer / vaccine / tumor antigen / NY-ESO-1 / CpG / 巖免疫療法 / CD4+T細胞 / CD8+T細胞 / 臨床試験 / 進行再発癌 / 癌ワクチン |
|---|
| Research Abstract |
The purpose of this study is to clarify the status of tumor antigen NY-ESO-1 expression in patients with cancer and the safety of cancer vaccination for patients with NY-ESO-1 expressing tumor. Initially, we constructed a positive control and a negative control for immunohistochemistry (IHC) to screen gene expression of NY-ESO-1. RT-PCR identified that HEC46 was NY-ESO-1 positive and TE8 negative. These cell lines were implanted into SCID mice subcutaneously and the tumors were resected. Paraffin embedded sections were made and appropriate condition of IHC was confirmed. NY-ESO-1 expression was analyzed by. IHC in 122 patients with esophageal squamous cell carcinoma (ESCC). The prognosis of patients with advanced ESCC expressing NY-ESO-1 was significantly better than that of patients with NY-ESO-1 negative tumor. Moreover, NY-ESO-1 expression was significantly correlated to the number of infiltrating CD4+T cells and CD8+T cells. Therefore, NY-ESO-1 expression would induce anti-tumor immunity of the host in patients with ESCC. Subsequently, clinical trial of cancer vaccination using NY-ESO-1 and CpG was performed. The purpose of the trial was to clarify the safety of the therapy. A patient with breast cancer was entered this trial and vaccinations were tried tree times. No side effect was observed and no clinical benefit was confirmed.
|
